EP1347769A2 - Cancer preventative effect of morinda citrifolia - Google Patents
Cancer preventative effect of morinda citrifoliaInfo
- Publication number
- EP1347769A2 EP1347769A2 EP01992025A EP01992025A EP1347769A2 EP 1347769 A2 EP1347769 A2 EP 1347769A2 EP 01992025 A EP01992025 A EP 01992025A EP 01992025 A EP01992025 A EP 01992025A EP 1347769 A2 EP1347769 A2 EP 1347769A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- dietary supplement
- fruit
- recited
- juice
- dmba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to inhibiting cancer.
- the present invention relates to the use of a dietary supplement that provides a cancer preventative effect at the initiation stage of carcinogenesis.
- free radicals Natural cell processes exist within the human body that use oxygen and produce toxins that are commonly referred to as "free radicals.” These free radicals may be highly reactive oxidizing substances that attach to and attack carbohydrates, deoxyribonucleic acid ("DNA”), enzymes, fats, and/or proteins within the body. The free radicals typically interfere with cellular function and reproduction, and may cause dysfunction and/or death of cells, tissues, and organs within the body. While a natural defense mechanism exists to reduce the cellular damage caused by the free radicals, the defense mechanism may become increasingly inefficient as the body ages. As such, damage caused by the free radicals has been implicated in several age-associated diseases, such as Alzheimer's disease, cancer, diabetes, heart disease, macular degeneration, and Parkinson's disease. In fact, suggestions have even been made that the damage caused by the free radicals may be an integral factor in the aging process of the human body.
- age-associated diseases such as Alzheimer's disease, cancer, diabetes, heart disease, macular degeneration, and Parkinson's disease. In fact,
- the amount of free radicals produced within the body is typically increased as the individual is exposed to cigarette smoke or various other toxins, such as mercury. Furthermore, the production of the free radicals is typically enhanced by exercise, since exercise instigates a need for oxygen within the body.
- Vitamin C Ascorbic acid
- Another technique used to reduce the cellular damage includes the regular consumption of biofavonoids, such as a mixture of catechins, phenolic acid, proan, and thocyanidins.
- biofavonoids such as a mixture of catechins, phenolic acid, proan, and thocyanidins.
- One such mixture is made from a highly bioactive substance called proanthocyanidins, obtained from the bark of the Maritime Pine in France and is the active ingredient in a product known as Pycnogenol ® .
- this mixture of biofavonoids may be absorbed in the skin and retained for as long as 72 hours to neutralize free radicals. It may improve circulation and may strengthen the immune system.
- Another technique used to reduce cellular damage includes the consumption of grape seed extract, which has been said to strengthen and protect living tissues.
- grape seed extract may strengthen blood vessels, improve the skin, and aid circulation. Furthermore, grape seed extract may be advantageous in defeating the hormone dihydrotesterone ("DHT"), which prevents the hair follicle growth cycle, thereby stimulating healthy hair growth.
- DHT hormone dihydrotesterone
- reports have claimed that various substances may be used to reduce cellular damage caused by the free radicals, contradictory results have been obtained that cause researchers to continue searching for answers. Accordingly, it would be an improvement in the art to augment or even replace the substances currently used with other substances to inhibit interference with cellular function and reproduction, thereby inhibiting cellular dysfunction.
- the present invention relates to inhibiting cancer.
- the present invention relates to the use of a dietary supplement that provides a cancer preventative effect at the initiation stage of carcinogenesis.
- Implementation of the present invention takes place in association with a dietary supplement that is processed from the fruit of the Indian Mulberry plant, scientifically known as Morinda citrifolia L.
- the dietary supplement includes reconstituted Morinda citrifolia fruit juice from pure juice puree of French Polynesia.
- the supplement may also include other natural juices, such as a natural grape juice concentrate, a natural blueberry juice concentrate, and/or another natural juice concentrate.
- the dietary supplement is not processed from dried or powdered Morinda citrifolia, rather liquid is extracted from the fruit of the Morinda citrifolia and used to create the dietary supplement.
- Titian Noni ® One implementation of the dietary supplement is referred to as "Tahitian Noni ® " and may be obtained from Morinda, Inc., which has a principal place of business located at 5152 N. Edgewood Dr. #100, Provo, UT, 84604.
- Use of the dietary supplements described herein include scavenging lipid hydroperoxides and superoxide anion free radicals within the body, thereby reducing cellular damage in the human body and/or providing a cancer preventative effect at the initiation stage of carcinogenesis.
- the dietary supplements include a combination of compounds that work at the cellular level to increase the positive functionality of cells in the body, including cell regeneration and cell function.
- the combination of compounds increases the ability of cells within the body to absorb and utilize nutrients such as vitamins and minerals, and stimulates the production of T-cells within the immune system.
- the T-cells are a type of lymphocyte or white blood cell that lead the attack against infections within the body, end the immune response, and or kill cancer cells and/or cells infected with a virus. Results from experiments described herein indicate that prevention of carcinogen-DNA adduct formation and the scavenging performed in accordance with the present invention contribute to cancer inhibition.
- one ounce of the dietary supplement is consumed per day to reduce toxins produced by natural cell processes with in the human body.
- consumption amounts may include more than one ounce per day or less than one ounce per day.
- the dietary supplement may be taken in the morning and/or before meals.
- the present invention relates to reducing inhibiting cancer.
- the present invention relates to the use of a dietary supplement that provides a cancer preventative effect at the initiation stage of carcinogenesis.
- the following disclosure of the present invention is grouped into three subheadings, namely "Dietary Supplement,” “Reducing Cellular Damage,” and “Inhibiting Cancer.”
- the utilization of the subheadings is for convenience of the reader only and is not to be construed as limiting in any sense.
- Dietary Supplement Embodiments of the present invention take place in association with a dietary supplement that is processed from the fruit of the Indian Mulberry plant, scientifically known as Morinda citrifolia L.
- the plant is an evergreen tree or shrub that is typically found in open tropical coastal regions, such as in Asia, Australia, and in islands of the Pacific Ocean. It is a member of the coffee family and typically grows in open lowlands, often on or along lava flows, and at edges of forests.
- the straight trunk, large, green, elliptical leaves, white tubular flowers, and ovoid, yellow fruit readily identify the Morinda citrifolia.
- the plant may be cultivated in gardens and has been naturalized in both moist and dry areas from sea level to about 1,300 feet above sea level.
- the Morinda citrifolia flourishes in the lush and unspoiled lands of French Polynesia, which includes Tahiti, and grows particularly large and lush in French Polynesia because of the ideal climate and soil conditions, and because the islands are generally still in their pristine condition.
- a mature plant may reach heights of 15 to 20 feet tall and may bear fruit throughout the year.
- the Morinda citrifolia typically includes coarse branches that are angular in cross section. The branches are thick and may be conspicuously marked with leaf scars. The leaves are ovate, thick, deeply veined, short-stemmed, green, and shiny, and may grow to lengths of over eight inches.
- Small white flowers of the Morinda citrifolia are born on globose, fused heads to form an inflorescence that is typically about an inch in diameter. While each of the heads produces many flower buds, typically only one or two of the buds open on a particular head during a given period of time.
- the flowers typically include five to seven lobed corollas that are often about one-third of an inch long in size.
- the flowers are closely packed and appear in various stages of development on the head. For example, green buds may be present near the apex of a particular head, while older flowers near the base of the head may have already opened and closed. Before the last flower near the apex of a head has bloomed, small yellowish-green fruitlets replace the flowers.
- the fruit of the Morinda citrifolia When the fruit of the Morinda citrifolia is mature, it is typically several inches long. Generally, the fruit is elongate in shape and includes a warty appearance that is caused by being marked with the polygonal outlines of the uneven individual fruitlet growth patterns. A pit, left as a scar from the corolla, is located within each of the polygonal outlines. If picked green, the fruit typically rots. As such, it is typically advantageous to allow the fruit to mature and ripen prior to picking.
- the skin Once the fruit of the Morinda citrifolia has matured, the skin is typically a whitish color and the flesh is a whitish-yellow color.
- the mature fruit is generally the size of a potato and resembles a small breadfruit.
- the seeds or kernels of the fruit are generally triangular in shape and are reddish-brown in color.
- An air sac, attached to one end of a seed, allows a detached seed to be buoyant.
- the Morinda citrifolia is rich in natural ingredients.
- the natural ingredients include: (from the leaves) alanine, anthraquinones, arginine, ascorbic acid, aspartic acid, calcium, beta-carotene, cysteine, cystine, glycine, glutamic acid, glycosides, histidine, iron, leucine, isoleucine, methionine, niacin, phenylalanine, phosphorus, proline, resins, riboflavin, serine, beta-sitosterol, thiamine, threonine, tryptophan, tyrosine, ursolic acid, and valine; (from the flowers) acacetin-7-o-beta-d(+)-glucopyranoside, 5,7-dimethyl- apigenin-4'-o-beta-d(+)- galactopyranoside, and 6,8-dimethoxy-3-methylanthraquino
- the fruit of the Morinda citrifolia includes health-enhancing enzymes that, for example, aid in easing inflammation, calming feelings of anxiety, supporting weight management, and promoting circulatory health in humans.
- the Morinda citrifolia is an adaptogenic herb that supports balanced body systems by responding to the body's need for stimulation or relaxation.
- Embodiments of the present invention relate to the creation and utilization of a dietary supplement that includes fruit juice from Morinda citrifolia.
- the dietary supplement includes reconstituted Morinda citrifolia fruit juice from pure juice puree of French Polynesia.
- the supplement may also include other natural juices, such as a natural grape juice concentrate, a natural blueberry juice concentrate, and/or another natural juice concentrate.
- the dietary supplement is not processed from dried or powdered Morinda citrifolia, rather liquid is extracted from the fruit of the Morinda citrifolia and used to create the dietary supplement, as will be discussed below.
- the dietary supplement is referred to as "Tahitian Noni ® " and may be obtained from Morinda, Inc., which has a principal place of business located at 5152 N. Edgewood Dr. #100, Provo, UT, 84604.
- the fruit of the Morinda citrifolia is harvested, either by hand or by mechanical equipment, when it is at least one inch long and up to 12 inches in diameter. At this time, the fruit generally has a color ranging from a dark green through a yellow-green up to a white color, and gradations of color in between. The fruit is thoroughly cleaned after being harvested and before being processed.
- the fruit is allowed to ripen or age from 0 to 14 days by being placed on equipment so that the ripening fruit is prevented from contacting the ground.
- the fruit is typically covered with a cloth or netting material during aging, but can be aged without being covered.
- the fruit is light in color, such as a light green, a light yellow, a white, or a translucent color.
- the fruit is inspected for spoilage and/or for excessively green color and hard firmness. Spoiled and hard green fruit is separated from the acceptable aged fruit.
- the acceptable aged fruit is typically placed in plastic lined containers for further processing and transport. While the containers of fruit may be held from 0 to 30 days, most containers are generally held for 7 to 14 days before processing.
- the containers can optionally be stored under refrigerated conditions prior to further processing.
- the fruit is unpacked from the storage containers and is processed through a manual or mechanical separator.
- the seeds and peel are separated from the juice and pulp.
- the juice and pulp may be packaged into containers for storage and transport.
- the containers may be stored in refrigerated, frozen, or room temperature conditions.
- the juice may be immediately processed into a finished juice product.
- Filtering equipment may be used to remove pulp from the juice.
- the filtering equipment may include a centrifuge decanter, a screen filter with a size from 1 micron up to 2000 microns (in one embodiment it is more preferably less than 500 microns), a filter press, reverse osmosis filtration, and/or any other standard commercial filtration devices.
- the operating filter pressure may range from 0.1 psig up to about 1000 psig.
- the flow rate may range from 0.1 g.p.m. up to 1000 g.p.m., and in one embodiment more preferably between 5 and 50 g.p.m.
- the wet pulp may be washed and filtered at least once to remove any juice from the pulp.
- the wet pulp typically has a fiber content of 10 to 40 percent by weight and may be pasteurized at a minimum temperature of 181°F (83°C) and then packed in drums for further processing or made into a high fiber product.
- the Morinda citrifolia juice and puree are typically blended in a homogenous blend, after which they are mixed with other ingredients, such as flavorings, sweeteners, nutritional ingredients, botanicals, extracts, and/or colorings.
- flavorings may include, but are not limited to, artificial and/or natural flavor or ingredients that contribute to palatability.
- sweeteners include, but are not limited to, natural sugars derived from corn, sugar beet, sugar cane, potato, tapioca, or other starch-containing sources that are chemically or enzymatically converted to crystalline chunks, powders, and/or syrups, or other sweeteners, including artificial or high intensity sweeteners, some of which are aspartame, sucralose, stevia, saccharin, etc.
- nutritional ingredients include vitamins (e.g., A, Bl through B12, C, D, E, Folic Acid, Pantothenic Acid, Biotin, etc.), minerals and/or trace elements (e.g., calcium, chromium, copper, cobalt, boron, magnesium, iron, selenium, manganese, molybdenum, potassium, iodine, zinc, and/or phosphorus), herbs and/or botanical extracts (e.g., alfalfa grass, bee pollen, chlorella powder, Dong Quai powder, Ecchinacea root, Gingko Biloba extract, Horsetail herb, Shitake mushroom, spirulina seaweed, and/or grape seed extract), bioactive chemicals (e.g., caffeine, ephedrine, L-carnitine, creatine, and or lycopene), and/or compounds.
- vitamins e.g., A, Bl through B12, C, D, E, Folic Acid, Pantothenic Acid, Bio
- the finished juice product is typically heated and pasteurized at a minimum temperature of 181°F (83°C) or higher, such as up to 212°F (100°C).
- the product is filled and sealed into a final container of plastic, glass, or another suitable material that withstands the processing temperatures.
- the containers are maintained at the filling temperature or may be cooled rapidly and then placed in a shipping container.
- the shipping containers are typically wrapped with a material and in a manner to maintain or control the temperature of the product in the final containers.
- embodiments of the present invention relate to reducing cellular damage in the human body.
- the free radicals are chemical species that possess an unpaired electron and are highly reactive oxidizing substances that attach to and attack carbohydrates, deoxyribonucleic acid ("DNA”), enzymes, fats, and/or proteins within the body.
- the free radicals are produced continuously in cells either as accidental by-products of metabolism or deliberately during, for example, phagocytosis.
- the free radicals typically interfere with cellular function and reproduction, and may cause dysfunction and/or death of cells, tissues and organs within the body.
- the amount of free radicals produced within the body is typically increased as the individual is exposed to cigarette smoke or various other toxins, such as mercury. Furthermore, the production of free radicals is typically enhanced by exercise, since exercise instigates a need for oxygen within the body. Excessive production of free radical-mediated oxidative alteration of fatty acids, also known as lipid peroxidation, leads to damage of cellular structure, enzymes, and/or tissues. Reactions occur in the body to form hydrogen peroxide and the highly toxic hydroxyl radical. A superoxide anion is converted to a hydroxyl radical and interacts with nitric oxide to form peroxinitrite, which degrades to form a hydroxyl radical.
- Peroxy radicals typically remove hydrogen from lipids, such as polyunsaturated fatty acids, resulting in a formation of lipid hydroperoxides and further propagate radical pathways by regeneration of alkyl radicals. Hydroperoxides have direct toxic effects for endothelial cells and degrade to form the hydroxyl radical. Hydroperoxides also form stable aldehydes, such as malondialdehyde (MDA), which damage membranes by facilitating the formation of protein cross-links and other end products.
- MDA malondialdehyde
- Hydroperoxyeicosatetraenoic acids HPETEs
- HTETEs Hydroperoxyeicosatetraenoic acids
- PLC protein kinase C
- HTETEs Hydroperoxyeicosatetraenoic acids
- HTETEs Hydroperoxyeicosatetraenoic acids
- HTETEs Hydroperoxyeicosatetraenoic acids
- HTETEs Hydroperoxyeicosatetraenoic acids
- HTETEs Hydroperoxyeicosatetraenoic acids
- HTETEs Hydroperoxyeicosatetraenoic acids
- HTETEs Hydroperoxyeicosatetraenoic acids
- HTETEs Hydroperoxyeicosatetraenoic acids
- a series of free radical catalyzed peroxidation products of arachidonic acid, called isoprostanes, is formed in a cyclo-oxygenase-independent manner and remains associated with membrane phospholipids until released by phospholipases.
- Defense mechanisms are critically important for the ultimate effect of oxidative stress and free radicals on cells and tissues within the body. Such defense mechanisms typically interrupt lipid peroxidation and inorganic free radical reaction or scavenge the reactive intermediates formed.
- the dietary supplement described herein is used to scavenge lipid hydroperoxides and superoxide anion free radicals within the body, thereby reducing cellular damage in the human body.
- the dietary supplement includes a combination of compounds that work at the cellular level to increase the positive functionality of cells in the body, including cell regeneration and cell function.
- the combination of compounds increases the ability of cells within the body to absorb and utilize nutrients such as vitamins and minerals.
- the combination has also stimulated the production of T-cells within the immune system.
- the T-cells are a type of lymphocyte or white blood cell that lead the attack against infections within the body, end the immune response, and/or kill cancer cells and/or cells infected with a virus.
- one fluid ounce (30 mL) of the dietary supplement is consumed per day to reduce toxins produced by natural cell processes with in the human body.
- other embodiments include the consumption of more than one fluid ounce per day or less than one fluid ounce per day.
- the dietary supplement is taken in the morning and/or before meals when the stomach is typically empty.
- Tahitian Noni provides a stronger effect to scavenge superoxide anion free radicals within the body than the regular intake of vitamin C, pycnogenol ® (maritime pine bark extract), or grape seed powder.
- Tahitian Noni ® may be used as a dietary supplement to scavenge lipid hydroperoxides and superoxide anion free radicals within the body. Examples of such experiments conducted and results achieved are more fully described in United States Provisional Patent Application Serial No.
- a dietary supplement having juice from the Morinda citrifolia may be used to scavenge lipid hydroperoxides and/or superoxide anion free radicals.
- a daily intake of Tahitian Noni ® has a stronger effect to scavenge superoxide anion free radicals than Vitamin C, Pycnogenol, ® (maritime pine bark extract), or grape seed powder.
- Tahitian Noni ® may be consumed together with Vitamin C, Pycnogenol, ® (maritime pine bark extract), and/or grape seed powder to scavenge lipid hydroperoxides and/or superoxide anion free radical.
- the utilization of the dietary supplement, such as Tahitian Noni, ® in accordance with the present invention allows an individual to escape or at least delay the onset of inherited diseases and age-associated declines in vision, hearing, and memory loss and other age-associated physiological declines.
- embodiments of the present invention relate to inhibiting cancer.
- embodiments of the present invention relate to the use of a dietary supplement that provides a cancer preventative effect at the initiation stage of carcinogenesis.
- various components include terpene compounds, anthraquinones, morindone, morindin, asperuloside, acubin, caproic acid, caprylic acid, damnacanthal, scopoletin, polysaccharide, and alkaloids.
- regular consumption of a dietary supplement that includes juice form the Morinda citrifolia provides a cancer preventive effect at the initiation stage of chemical carcinogenesis by preventing the carcinogen-DNA adduct formation.
- DMBA 7, 12-dimethylbenza anthrancine
- LPO lipid hydroperoxide quenching activity of the dietary supplement was examined in vitro by LPO assay.
- LPO oxidized leucomethylene blue to methylene blue in the presence of hemoglobin. The resultant blue color is quantified spectrophotometrically (660 nm).
- Authentic cumene hydroperoxide was used as a standard to monitor the LPO quenching activity of the dietary supplement.
- the superoxide anion radical (“SAR”) scavenging activity of the dietary supplement was examined in vitro by tetrazolium nitroblue (“TNB”) assay. SAR reduced TNB into formazan blue, which absorbed at 602 nm.
- a SAR scavenger reduced the absorbence by reacting with SAR.
- phenazine methosulfate was used as a catalyst.
- the activity of the dietary supplement was compared to that of three known antioxidants against SAR in vitro at the recommended daily dose per serving by U.S. RDAs (U.S. Government Recommended Daily Allowances) or by manufacturers.
- Sixty mg of Vitamin C obtained from Roche Vitamins Inc. Parsippany, NJ
- 60 mg of Pycnogenol® obtained from Twin Laboratories Inc., Ronkonkoma, New York 11779
- 100 mg of grape seed powder obtained from DNP International Co., Inc.
- DNA adduct formation was reduced in female SD rats drinking 10% of the dietary supplement. Furthermore, the levels of DMBA-DNA adducts were reduced by 30% in the heart, 41% in the lungs, 42% in the liver, and 80% in the kidneys. Even more dramatic results were obtained in male C57 BL-6 mice. Ten percent of the dietary supplement was able to prevent DMBA-DNA adduct formation by 60% in the heart,
- Typical profiles of DMBA-DNA adducts in control liver (A) and lung (C) of female SD rats were induced.
- the densities and the numbers of DNA adducts in liver (B) and lung (D) were reduced in 10% of the dietary supplement group.
- the level of DMBA adducts was prevented by 42% in the liver, 41% in the lung, when compared to the control group
- the films were exposed at -80 ⁇ C for three hours
- Typical profiles of DMBA-DNA adducts in control heart (A) and kidney (C) of female SD rats were induced.
- the densities and the numbers of DNA adducts in heart (B) and kidney (D) were reduced in 10% dietary supplement group
- the level of DMBA adducts was prevented by 30% in the heart, 80% in the kidney, when compared to the control group.
- the films were exposed at -80 D C for three hours.
- the activity of the dietary supplement was observed inn vitro.
- a dose- dependent curve of the SAR scavenging activity of the dietary supplement in vitro was obtained by TNB assay (see below).
- a dose-dependent curve of the LPO quenching activity of the dietary supplement in vitro was also observed by LPO assay (see also below).
- the SAR scavenging activity of the dietary supplement was compared to that of Vitamin C, grape seed powder (“GSP”), and Pycnogenol® ("PYC”). Under the experimental conditions, the SAR scavenging activity of the dietary supplement was shown to be 2.8 times that of Vitamin C, 1.4 times that of PYC, and 1.1 times that of GSP.
- the results of the experiment indicate that 10% the dietary supplement reduced the DMBA-DNA adduct formation in different organs of female SD rats and male C57 Bl-6 mice. Adducts particularly reduced the most in the kidneys. Since DNA adduct formation is a step in chemical carcinogenesis, the preventive effect of the dietary supplement on DMBA adduct formation indicates that the use of the dietary supplement prevents cancer at the initiation stage of chemical carcinogenesis.
- the strong activities of the dietary supplement against SAR and LPO were observed in vitro by TNB and LPO assays. Since the dietary supplement showed higher activity, it provides that the dietary supplement protects cells or lipids form oxidative modification mediated by SAR. Both the carcinogen-DNA adduct prevention and the antioxidant properties contribute to the cancer preventive effect of the dietary supplement in accordance with the present invention.
- the mechanism by which the dietary supplement prevents the formation of DMBA-DNA adducts is as follows:
- the dietary supplement inhibits phase I enzyme activity while enhancing phase II enzyme and DNA repair enzyme activities.
- the dietary supplement blocks the redox-cycling between the carcinogen and their metabolites by interrupting the metabolic pathway, scavenging oxygen free radicals, and quenching the consequent LPO.
- the dietary supplement also affects redox- sensitive signal transduction pathways and alters gene expression. Therefore, the interactions of carcinogens, oxygen free radicals, and LPO are changed by the dietary supplement.
- a dietary supplement in accordance with the present invention provides a cancer preventive effect at the initiation stage of chemical carcinogenesis.
- a dietary supplement in accordance with the present invention inhibits cancer and other diseases, while maintaining overall good health.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25141700P | 2000-12-05 | 2000-12-05 | |
US251417P | 2000-12-05 | ||
US09/997,588 US20020068102A1 (en) | 2000-12-01 | 2001-11-29 | Reducing cellular damage in the human body |
PCT/US2001/046835 WO2002045654A2 (en) | 2000-12-05 | 2001-12-05 | Cancer preventative effect of morinda citrifolia |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1347769A2 true EP1347769A2 (en) | 2003-10-01 |
EP1347769A4 EP1347769A4 (en) | 2008-02-20 |
Family
ID=26941594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01992025A Withdrawn EP1347769A4 (en) | 2000-12-05 | 2001-12-05 | Cancer preventative effect of morinda citrifolia |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1347769A4 (en) |
JP (1) | JP2004529077A (en) |
AU (1) | AU2002232504A1 (en) |
WO (1) | WO2002045654A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6254913B1 (en) * | 1999-08-27 | 2001-07-03 | Morinda, Inc. | Morinda citrifolia dietary fiber and method |
US8574642B2 (en) | 2000-12-05 | 2013-11-05 | Tahitian Noni International, Inc. | Antiviral Morinda citrifolia L. based formulations and methods of administration |
US7244463B2 (en) | 2005-10-18 | 2007-07-17 | Tahitian Noni International, Inc. | Garcinia mangostana L. enhanced animal food product |
US8790727B2 (en) | 2000-12-05 | 2014-07-29 | Tahitian Noni International, Inc. | Morinda citrifolia and iridoid based formulations |
US8652546B2 (en) | 2007-09-06 | 2014-02-18 | Tahitian Noni International, Inc. | Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals |
WO2002083159A1 (en) * | 2001-04-17 | 2002-10-24 | Morinda, Inc. | Palliative effects of morinda citrifolia oil and juice |
US7442395B2 (en) | 2002-11-14 | 2008-10-28 | Tahitian Noni International, Inc. | Formulation for treating candidiasis using Morinda citrifolia |
US20050037101A1 (en) * | 2003-08-12 | 2005-02-17 | Mian-Ying Wang | Preventative effects of morinda citrifolia on mammary breast cancer |
US8025910B2 (en) | 2006-05-12 | 2011-09-27 | Tahitian Noni International, Inc. | Method and composition for administering bioactive compounds derived from Morinda citrifolia |
US8535741B2 (en) | 2006-05-12 | 2013-09-17 | Morinda, Inc. | Method and composition for administering bioactive compounds derived from Morinda citrifolia |
KR101915726B1 (en) * | 2017-03-08 | 2018-11-06 | 한국교통대학교 산학협력단 | Food additive composition having anticancer activity, kimchi seasoning composition and anti-cancerous kimchi including it |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039632A1 (en) * | 1996-04-22 | 1997-10-30 | Henkel Corporation | Natural antioxidant composition |
FR2783137A1 (en) * | 1998-09-10 | 2000-03-17 | Royal Tahiti Noni | Preparation of composition based on extract of fruit of Polynesian plant Morinda Citrifolia, for use as invigorating-health improving drink, involves filtration, de-pectinization, heating and final filtration |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288491A (en) * | 1992-09-24 | 1994-02-22 | Herbert Moniz | Noni (Morinda Citrifolia) as a pharmaceutical product |
-
2001
- 2001-12-05 AU AU2002232504A patent/AU2002232504A1/en not_active Abandoned
- 2001-12-05 JP JP2002547440A patent/JP2004529077A/en active Pending
- 2001-12-05 WO PCT/US2001/046835 patent/WO2002045654A2/en active Application Filing
- 2001-12-05 EP EP01992025A patent/EP1347769A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039632A1 (en) * | 1996-04-22 | 1997-10-30 | Henkel Corporation | Natural antioxidant composition |
FR2783137A1 (en) * | 1998-09-10 | 2000-03-17 | Royal Tahiti Noni | Preparation of composition based on extract of fruit of Polynesian plant Morinda Citrifolia, for use as invigorating-health improving drink, involves filtration, de-pectinization, heating and final filtration |
Non-Patent Citations (5)
Title |
---|
BOUHAMIDI R ET AL: "High protection by grape seed proanthocyanidins (GSPC) of polyunsaturated fatty acids against UV-C induced peroxidation" COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES. SERIE III: SCIENCES DE LA VIE, ELSEVIER, AMSTERDAM, NL, vol. 321, no. 1, January 1998 (1998-01), pages 31-38, XP004270140 ISSN: 0764-4469 * |
GANAL C A ET AL: "THE EFFECT OF NONI FRUIT EXTRACT (MORINDA CITRIFOLIA INDIAN MULBERRY) ON JTHYMOCYTES OF BALB/C MOUSE" FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 7, no. 3/4, 28 March 1993 (1993-03-28), page A866, XP001074327 ISSN: 0892-6638 * |
PALOMINO O ET AL: "Study of polyphenols in grape berries by reversed-phase high-performance liquid chromatography" JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 870, no. 1-2, February 2000 (2000-02), pages 449-451, XP004187345 ISSN: 0021-9673 * |
See also references of WO0245654A2 * |
WANG M Y ET AL: "CANCER PREVENTIVE EFFECT OF MORINDA CITRIFOLIA (NONI)" ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 952, December 2001 (2001-12), pages 161-168, XP008016136 ISSN: 0077-8923 & DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, WANG M Y ET AL: "Cancer Preventive effect of Morinda citrifolia (Noni)" Database accession no. PREV200200120175 & ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. CANCER PREVENTION: MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS NEW YORK ACADEMY OF SCIENCES {A}, 2 EAST 63RD STREET, NEW YORK, NY, 10021, USA SERIES : ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (ISSN 0077, 2001, pages 161-168, CONFERENCE ON CANCER PREVENTION: MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS; NEW YORK, NEW YORK, USA; NOVEMBER 10-11, 2000 ISSN: 1-57331-350-5 1-57331-351-3 * |
Also Published As
Publication number | Publication date |
---|---|
JP2004529077A (en) | 2004-09-24 |
WO2002045654A2 (en) | 2002-06-13 |
EP1347769A4 (en) | 2008-02-20 |
WO2002045654A3 (en) | 2002-09-06 |
WO2002045654A9 (en) | 2004-02-12 |
AU2002232504A1 (en) | 2002-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020068102A1 (en) | Reducing cellular damage in the human body | |
US20050202109A1 (en) | Methods and compositions for inhibiting monoamine oxidase and catechol-o-methyltransferase | |
US20050186296A1 (en) | Profiles of lipid proteins and inhibiting HMG-CoA reductase | |
US20070160700A1 (en) | Methods and compositions for reactivating acetylcholinesterase | |
US20070166416A1 (en) | Formulations and Methods for Preventing and Treating Substance Abuse and Addiction | |
US20050202108A1 (en) | Methods and compositions for inhibiting angiotensin converting and chymase enzymes | |
EP1771187A2 (en) | Morinda citrifolia leaf extract compositions and methods of obtaining the same | |
US20060280818A1 (en) | Nicotinic acetylcholine receptor antagonist | |
AU2004291030A1 (en) | Preventative effects of morinda citrifolia on mammary breast cancer | |
WO2006050012A2 (en) | Morinda citrifolia based compositions and methods for inhibiting xanthine oxidase | |
JP2007016015A (en) | Inhibition of histone deacetylase and tumor necrosis factor converting enzyme | |
WO2002045654A2 (en) | Cancer preventative effect of morinda citrifolia | |
US20080206376A1 (en) | Methods and compositions for inhibiting angiotensin converting and chymase enzymes | |
WO2007064607A2 (en) | Formulation and methods for use of morinda citrifolia seed oil | |
WO2007064601A2 (en) | Antiviral morinda citrifolia l. based formulations and methods of administration | |
US20090022828A1 (en) | Methods and compositions for inhibiting angiotensin converting and chymase enzymes | |
US8025910B2 (en) | Method and composition for administering bioactive compounds derived from Morinda citrifolia | |
US20100034905A1 (en) | Method of treating burns | |
US8535741B2 (en) | Method and composition for administering bioactive compounds derived from Morinda citrifolia | |
US20090196944A1 (en) | Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS | |
WO2005120538A1 (en) | Morinda citrifolia-based formulation 5-lox and 15-lox | |
WO2007064547A2 (en) | Morinda citrifolia based formulation and methods for weight management | |
JP2007314461A (en) | Nicotinic acetylcholine receptor antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030617 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
R17D | Deferred search report published (corrected) |
Effective date: 20020906 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TAHITIAN NONI INTERNATIONAL, INC |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WANG, MIAN-YING Inventor name: STORY, STEPHEN, P. Inventor name: JENSEN, CLAUD, JARAKAE Inventor name: SU, CHEN, XING |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080123 |
|
17Q | First examination report despatched |
Effective date: 20080704 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100701 |